About Peptide Hub — Evidence-Based Peptide Education

Our mission

Peptide Hub exists because accurate, organized peptide science information is hard to find. Most resources are either overly commercial, buried in paywalled journals, or written for specialists with years of biochemistry training. We built Peptide Hub to close that gap — a free, independent educational platform that presents research peptide science clearly, accurately, and accessibly for anyone who approaches health and performance through a science-driven lens.

We are not affiliated with any peptide supplier, pharmacy, or commercial operation. We do not sell products, accept advertising, or receive commissions. Our only purpose is to organize and present peptide research in a way that is genuinely useful.

What you will find here

The Peptide Hub database covers 79 research peptides across 25 categories — from healing and repair peptides like BPC-157 and TB-500, to weight management compounds including GLP-1, GLP-1 Dual Agonist, and GLP-3 triple agonists, mitochondrial peptides like MOTS-c, SS-31, and Humanin, brain and mood peptides including Semax, Selank, Noopept, and Pinealon, and longevity bioregulators including Epithalon and Thymalin. Every entry includes complete dosing specifications, BAC water reconstitution ratios, injection method guidance, timing protocols, and an interactive dose calculator.

Beyond the database, you will find a 109-term peptide glossary covering everything from amino acid structures to mitochondrial signaling pathways, a comprehensive FAQ section addressing the most common research questions, and Pepe — our on-site AI peptide expert — available to answer questions in plain language at any time.

Who this site is for

Peptide Hub is built for researchers, biohackers, functional medicine practitioners, longevity-focused individuals, and anyone who wants to understand peptide science at a deeper level. Whether you are new to peptides and trying to understand the difference between BPC-157 and TB-500, or an experienced researcher comparing GLP-1 Dual Agonist to triple agonist mechanisms, you will find the depth you need here.

All content is presented for educational and research purposes only and does not constitute medical advice. We always recommend consulting a qualified healthcare professional before making any decisions about compounds discussed on this site.

Our approach to evidence

We distinguish clearly between compounds with robust preclinical and human clinical evidence (such as GLP-1 agonists, SS-31/elamipretide which received FDA accelerated approval for Barth syndrome in September 2025, and tesamorelin which is FDA-approved for HIV-associated lipodystrophy) and compounds that remain primarily preclinical. When evidence is retracted or contested — as with Dihexa following the April 2025 retraction of its foundational mechanism paper — we say so clearly on the relevant page. We believe transparency about evidence quality is fundamental to responsible science communication.

Our primary research references include PubMed, ClinicalTrials.gov, and peer-reviewed journals. We encourage all users to follow citations back to primary sources.

Get in touch

Have a question about a specific peptide, a correction to suggest, or a research topic you would like to see covered? Use our contact form — we read every message. You can also ask Pepe, our AI peptide expert, directly on any page of the site.

"Empowering peptide discovery through science and connection."